ClinicalTrials.gg
CompletedNCT05305560SAIVEUpdated Dec 31, 2024Results posted

A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention

A Phase 2 interventional study of Ivermectin Tablets and Matching placebo tablets in COVID-19, sponsored by MedinCell S.A. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by MedinCell S.A · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing ivermectin in COVID-19 — 2 open to participants now, 2 under way, 1 of them phase 3. Ivermectin · COVID-19.

Enrollment
17th of 55
400 · median 180
Started
2022
with 4 others
Phase 2
13 of 55
1 open now
Registered
51st of 55
by date
Lead sponsor
2 of 55
MedinCell S.A

Among the 55 studies testing ivermectin in COVID-19, this one is the 17th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 2, and was the 51st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 55 studies testing ivermectin in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing ivermectin in COVID-19, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis

Read the detailed description

This trial comprises a total observation period of up to 56 days (an on-treatment period of up to 28 days and a safety follow-up of up to 28 days).

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Prophylaxis
  • RT-PCR test
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 65 years, inclusive.
  2. Body weight >45 kg.
  3. >18.5.
  4. Close contact with a person who has a PCR-confirmed SARS-CoV-2 infection within 5 days before screening.
  5. Only one member in the same household will be enrolled.
  6. Participants must be able to give and comply with the study's scheduled events/visits and study assessments.
  7. SARS-CoV-2 positive index case must be able to give consent to enable collection of the documented positive PCR test.
  8. Female participants of must use a highly effective method of for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breast-feeding.
  2. Participants who have been administered COVID-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study.
  3. A positive COVID-19 result (PCR or antigen test) within 8 days of screening.
  4. Presence of typical COVID-19 symptoms (fever >38°C, SpO2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening.
  5. to any component of ivermectin.
  6. Participants who have been administered ivermectin within 30 days prior to screening.
  7. Participation in another interventional trial within the last 30 days or 5 half-lives of the IMP of the other trial, whichever comes first.
  8. Participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.).
  9. History of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors.
  10. Current use of monoclonal antibodies for the treatment of COVID-19.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Active IMP

    Drug: Ivermectin Tablets

  • Placebo comparator
    Placebo

    Drug: Matching placebo tablets

Interventions

  • Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.

  • DrugMatching placebo tablets

    Daily placebo tablets intake for 28 days

06

What researchers measure

Primary outcomes

  1. COVID-19 Prophylaxis

    Number of laboratory-confirmed COVID-19 infections in each group between baseline and Day 28

    Time frame: From Day 1 to Day 28

Secondary outcomes

  1. COVID-19 Symptoms Development

    Number of symptomatic Participants according to the WHO COVID-18 scale

    Time frame: From Day 1 to Day 28

  2. COVID-19 Prophylaxis Timeframe

    Time to change from baseline in negative RT-PCR to positive RT-PCR

    Time frame: From Day 1 to Day 28

  3. COVID-19 Hospitalisations

    Proportion of COVID-19 related hospitalisations

    Time frame: From Day 1 to Day 56

  4. COVID-19 Mortality

    Proportion of COVID-19 related mortality

    Time frame: From Day 1 to Day 56

  5. To Assess the Safety and Tolerability of IVM Given for a Period of 28 Days

    Descriptive comparison of AE rates and severity/seriousness between IVM and placebo

    Time frame: 56 days

07

Results

Posted Dec 10, 2024

Participant flow

Participant flow — Overall Study
MilestoneActive IMPPlacebo
Started200199
Completed200199
Not completed00

Outcome measures

PrimaryCOVID-19 Prophylaxis

Number of laboratory-confirmed COVID-19 infections in each group between baseline and Day 28

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
COVID-19 Prophylaxis
ParticipantsActive IMPPlacebo
COVID-19 Prophylaxis30105
SecondaryCOVID-19 Symptoms Development

Number of symptomatic Participants according to the WHO COVID-18 scale

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
COVID-19 Symptoms Development
ParticipantsActive IMPPlacebo
COVID-19 Symptoms Development2897
SecondaryCOVID-19 Prophylaxis Timeframe

Time to change from baseline in negative RT-PCR to positive RT-PCR

Time frame:
From Day 1 to Day 28
Reported as:
Mean · days
COVID-19 Prophylaxis Timeframe
daysActive IMPPlacebo
COVID-19 Prophylaxis Timeframe9 ± 1.398.10 ± 2.14
SecondaryCOVID-19 Hospitalisations

Proportion of COVID-19 related hospitalisations

Time frame:
From Day 1 to Day 56
Reported as:
Number · participants
COVID-19 Hospitalisations
participantsActive IMPPlacebo
COVID-19 Hospitalisations00
SecondaryCOVID-19 Mortality

Proportion of COVID-19 related mortality

Time frame:
From Day 1 to Day 56
Reported as:
Number · participants
COVID-19 Mortality
participantsActive IMPPlacebo
COVID-19 Mortality00
SecondaryTo Assess the Safety and Tolerability of IVM Given for a Period of 28 Days

Descriptive comparison of AE rates and severity/seriousness between IVM and placebo

Time frame:
56 days
Reported as:
Number · participants
To Assess the Safety and Tolerability of IVM Given for a Period of 28 Days
participantsActive IMPPlacebo
Adverse events49109
Serious adverse events00

Adverse events

Collected over 56 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active IMP0/200 (0%)0/200 (0%)49/200 (24.5%)
Placebo0/199 (0%)0/199 (0%)109/199 (54.8%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventActive IMPPlacebo
COVID-19Infections and infestations30/200109/199
C-reactive protein increasedInvestigations0/2005/199
HeadacheNervous system disorders4/2001/199
DiarrhoeaGastrointestinal disorders4/2000/199
NauseaGastrointestinal disorders4/2001/199
Aspartate aminotransferase increasedInvestigations3/2000/199
PalpitationsCardiac disorders0/2002/199
DysmenorrheaReproductive system and breast disorders2/2001/199
FatigueGeneral disorders2/2001/199
Alanine aminotransferase increasedInvestigations2/2000/199

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active IMPPlaceboTotal
Mean40.86 ± 11.8439.99 ± 12.0340.42 ± 11.93
Sex: Female, Male
Sex: Female, Male(Participants)Active IMPPlaceboTotal
Female8190171
Male119109228
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Active IMPPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Active IMPPlaceboTotal
Bulgaria200199399
08

Study locations

1 site
  • Medical Center Medic Ltd.
    Sofia, Bulgaria
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Sep 2022, 5 months.

Results were first posted in Dec 2024, 2 years 2 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 5 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Mar 31, 2022
StartActual
Mar 25, 2022
Primary completionActual
Sep 15, 2022
CompletionActual
Oct 13, 2022
Results first posted
Dec 10, 2024
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05305560
Lead sponsor
MedinCell S.A
Collaborators
Violaine Desort-Hénin, DVM
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Mar 25, 2022
Primary completion
Sep 15, 2022
Completion
Oct 13, 2022
Results posted
Dec 10, 2024
Last update
Dec 31, 2024

Study contacts

Anna Kostova, MD
principal investigator · Medical Center Medic Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion